INOVIO Doses First Subject in INO-4800 Trial to Prevent COVID-19

INOVIO has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate, as part of its Phase 2/3 clinical trial, called INNOVATE (INovio INO-4800 Vaccine Trial for Efficacy). The Phase 2 segment of the trial will enroll approximately 400 participants who are 18 years or older at up to 17 U.S. sites to evaluate safety and immunogenicity in order to confirm the dose(s) for the subsequent efficacy evaluation as part of the Phase 3 segment of the trial. INOVIO plans to fully enroll the Phase 2 segment of the trial by the end of this month.

INNOVATE is a randomized, blinded, placebo-controlled safety and efficacy evaluation of INO-4800 being conducted in adults in the U.S. The INNOVATE trial is funded by the U.S. Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA).

"We're pleased to move into the Phase 2 segment of our 2/3 trial on the pathway to establish our DNA technology as an integral component of the pandemic response given its potential for an outstanding safety profile and its demonstrable thermostability. I am particularly grateful for the confidence instilled in us by the U.S. Department of Defense, a partnership to ensure that healthcare workers, frontline responders, our elderly as well as our military servicemembers are protected from COVID-19," Dr. J. Joseph Kim, INOVIO's President & CEO said.

The Phase 2 segment of the trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization to receive either INO-4800 or placebo to confirm the more appropriate dosing level(s) for each of three age groups (18-50 years, 51-64 years and 65 years and older) at high risk of SARS-CoV-2 exposure for the subsequent Phase 3 efficacy evaluation.

The DoD has agreed to provide funding for both the Phase 2 and Phase 3 segments of INNOVATE, in addition to the $71 million of funding previously announced in June for the large-scale manufacture of the company's proprietary next generation smart device CELLECTRA® 3PSP and the procurement of CELLECTRA® 2000 devices.

INO-4800 is INOVIO's prophylactic DNA vaccine candidate against SARS-CoV-2, the novel coronavirus that causes COVID-19. INOVIO is leveraging its extensive experience with INO-4700, its DNA vaccine against another important coronavirus, the Middle East Respiratory Syndrome (MERS), that is soon to be evaluated in a Phase 2 clinical trial.

INO-4800 is the only nucleic-acid based vaccine that is stable at room temperature for more than a year and does not need to be frozen during transport or storage, which are important considerations when preparing for mass immunizations.